Lokelma for RAAS Maximisation in CKD & Heart Failure.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.
Also called NCT05004363
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 112 participants
- Sponsor
- St George's, University of London
- Registry
-
NCT05004363 -
2020-002946-18
-
- Other papers using this trial's data
- Rapid Renin Angiotensin Aldosterone System inhibitor optimisation in patients with chronic kidney disease and heart failure with reduced ejection fraction using potassium binder: a randomised, double-blinded, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05004363. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-19 (actual); primary completion 2024-07-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Lokelma for RAAS Maximisation in CKD & Heart Failure.
- Acronym
- LIFT
- Condition
- Chronic Kidney Diseases
- Condition
- Hyperkalemia
- Condition
- ACE Inhibitor Induced Hyperkalaemia
- Condition
- Mineralocorticoid Resistant Hyperkalemia
- Intervention (Drug)
- Lokelma Oral Product
- Lead sponsor
- St George's, University of London
Record details
- Record id
cardio:ct-nct05004363- Content hash
6fbf3f9ccd7a573d89a556d00e1098d9ed61f50dbf08702f9557902bf509d4ce